Enanta Pharmaceuticals, Inc.
ENTA · FY2025 · Fiscal year ended Sep 30, 2025 · 10-K filed Nov 2025
Open the dashboardInfographicSummary
FY2025 key figures
| $ | FY2025 | FY2024 | Change |
|---|---|---|---|
| Revenue | $65.3M | $67.6M | −3.4% |
| Operating income | −$85.3M | −$122M | +29.9% |
| Net income | −$81.9M | −$116M | +29.4% |
Latest quarter: Q3 FY2026
Form 10-Q · Three months ended Jun 30, 2026 · filed Aug 12, 2026
| $ | Q3 FY2026 | Year earlier | Change |
|---|---|---|---|
| Revenue | $14.4M | $18.3M | −21.3% |
| Operating income | −$17.2M | −$18.9M | +9.0% |
| Net income | −$19.5M | −$18.3M | −6.6% |
Q3 FY2026 dashboardQ3 FY2026 infographic
Questions
- What was Enanta's revenue in FY2025?
- $65.3M in FY2025 (Fiscal year ended Sep 30, 2025), −3.4% vs $67.6M a year earlier, per its 10-K filed Nov 2025.
- Was Enanta profitable in FY2025?
- No: net income was −$81.9M and operating income −$85.3M in FY2025.
- What was Enanta's revenue in Q3 FY2026?
- $14.4M (−21.3% vs a year earlier), per its Form 10-Q filed Aug 12, 2026.